PALATIN TECHNOLOGIES INC (PTN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$10.2M
Cash & Equivalents
$10.8M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$18M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06565611 | A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity | PHASE2 | Active Not Recruiting | 108 |
| NCT05466890 | Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) | PHASE2 | Active Not Recruiting | 16 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.